Navigation Links
EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts
Date:3/30/2009

- Supports US Drug Discovery Activities in Neurodegenerative Diseases-

ROCKLAND, Mass., March 30 /PRNewswire/ -- EMD Serono, Inc. announced today that it will open a site in Cambridge, Massachusetts to support its growing Research function. The Cambridge laboratory space will accommodate EMD Serono's US drug discovery activities in neurodegenerative diseases such as multiple sclerosis (MS), which will augment the company's existing US research in oncology and fertility. EMD Serono expects to occupy the site with nearly 50 scientists across disciplines, including neurobiology, pharmacology and chemistry, to work at the location.

"This research expansion further supports EMD Serono's commitment to develop and deliver innovative therapies for patients in our areas of focus," said Fereydoun Firouz, President and CEO, EMD Serono, Inc. "EMD Serono is following our outlined strategy to broaden our research capabilities by expanding our footprint in the state of Massachusetts in close proximity to leading academic centers and qualified expertise that can be complimentary to our organization and add researchers that can grow with our team. I am proud to be delivering on our plans of continued investments to firmly establish a foothold within the state and with this expansion we confirm and reinforce our strong commitment to neurodegenerative diseases and MS research."

"EMD Serono's continued expansion in Massachusetts confirms the leadership's commitment to growing in the state and providing talented individuals with potential employment opportunities as they work to develop new treatment options for the many patients in need," said Robert Coughlin, President and CEO of Massachusetts Biotechnology Council. "This is an important announcement, during this time of economic pressure that gives some reassurance that leading biopharmaceutical companies such as EMD Serono have stability with hiring, expanding and investing plans still on track."

In 2008, EMD Serono announced a planned expansion of its Billerica laboratory to create a center of excellence in discovery, which is scheduled for completion in 2010. The Cambridge satellite laboratory, which will be approximately 18,000 square feet in size, will address the company's immediate need to secure necessary laboratory space for its additional scientists as a result of accelerated employee growth.

EMD Serono completed the first Phase III trial of an oral multiple sclerosis drug, cladribine, which is targeted for registration filing later this year. With these additional capabilities the company plans to focus research and development efforts towards Parkinson's disease, and other neurodegenerative diseases.

About EMD Serono, Inc.

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives.

The company has strong market positions in neurodegenerative diseases, with Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R) (somatropin (rDNA origin) for injection) and Serostim(R) (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alfa for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alfa injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com


'/>"/>
SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
2. iMedica Corporation Announces the Release of Patient Relationship Manager 2009
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
5. Thomson Reuters Announces 100 Top Hospitals Award Winners
6. iMedica Corporation Announces Release of Patient Relationship Manager 2009
7. KMSI Announces KMx Update That Provides eLearning, Knowledge Management and Collaboration Tools for Apple iPhone and Other Mobile Devices
8. Academy of Lymphatic Studies Announces Accelerated Hybrid Online Program
9. Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
10. Nationwide Medical/Surgical Announces Availability of Tamiflu for the 2009-2010 Influenza Season
11. Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its ... charitable foundation serving the footwear industry, has broken all previous participation records in ... companies across 23 states during the months of April and May, the 2016 ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... , ... For those who skip meals occasionally (which is pretty much everyone), ... many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of ... show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy during ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
Breaking Medicine Technology: